Infant rhesus macaques immunized against SARS-CoV-2 are protected against heterologous virus challenge 1 year later.

Autor: Milligan EC; Department of Microbiology and Immunology, Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Olstad K; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Williams CA; Department of Pediatrics, Weill Cornell Medical College, New York, NY 10065, USA., Mallory M; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Cano P; Lineberger Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Cross KA; Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Munt JE; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Garrido C; Center for Immunology and Infectious Diseases, University of California at Davis, Davis, CA 95616, USA., Lindesmith L; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Watanabe J; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Usachenko JL; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Hopkins L; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Immareddy R; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Shaan Lakshmanappa Y; Center for Immunology and Infectious Diseases, University of California at Davis, Davis, CA 95616, USA., Elizaldi SR; Center for Immunology and Infectious Diseases, University of California at Davis, Davis, CA 95616, USA.; Graduate Group in Immunology, University of California at Davis, Davis, CA 95616, USA., Roh JW; Center for Immunology and Infectious Diseases, University of California at Davis, Davis, CA 95616, USA.; Graduate Group in Immunology, University of California at Davis, Davis, CA 95616, USA., Sammak RL; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Pollard RE; School of Veterinary Medicine, University of California at Davis, Davis, CA 95616, USA., Yee JL; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Herbek S; Department of Pediatrics, Weill Cornell Medical College, New York, NY 10065, USA., Scobey T; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Miehlke D; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA., Fouda G; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA., Ferrari G; Duke Human Vaccine Institute, Duke University Medical Center, Durham, NC 27710, USA.; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA.; Department of Molecular Genetics and Microbiology, Duke University Medical Center, Durham, NC 27710, USA., Gao H; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Shen X; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Kozlowski PA; Department of Microbiology, Immunology and Parasitology, Louisiana State University Health Sciences Center, New Orleans, LA 70112, USA., Montefiori D; Department of Surgery, Duke University School of Medicine, Durham, NC 27710, USA., Hudgens MG; Department of Biostatistics, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Edwards DK; Moderna Inc., Cambridge, MA 02139, USA., Carfi A; Moderna Inc., Cambridge, MA 02139, USA., Corbett KS; Department of Immunology and Infectious Diseases, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA., Graham BS; Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD 20852, USA., Fox CB; Access to Advanced Health Institute, Seattle, WA 98102, USA.; Department of Global Health, University of Washington, Seattle, WA 98105, USA., Tomai M; 3M Corporate Research Materials Laboratory, Saint Paul, MN 55144, USA., Iyer SS; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA.; Center for Immunology and Infectious Diseases, University of California at Davis, Davis, CA 95616, USA., Baric R; Department of Epidemiology, Gillings School of Global Public Health, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA., Reader R; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA., Dittmer DP; Department of Microbiology and Immunology, Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.; Department of Pediatrics, Weill Cornell Medical College, New York, NY 10065, USA., Van Rompay KKA; California National Primate Research Center, University of California at Davis, Davis, CA 95616, USA.; Department of Pathology, Microbiology and Immunology, University of California at Davis, Davis, CA 95616, USA., Permar SR; Department of Pediatrics, Weill Cornell Medical College, New York, NY 10065, USA., De Paris K; Department of Microbiology and Immunology, Children's Research Institute, School of Medicine, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599, USA.
Jazyk: angličtina
Zdroj: Science translational medicine [Sci Transl Med] 2023 Mar; Vol. 15 (685), pp. eadd6383. Date of Electronic Publication: 2023 Mar 01.
DOI: 10.1126/scitranslmed.add6383
Abstrakt: The U.S. Food and Drug Administration only gave emergency use authorization of the BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines for infants 6 months and older in June 2022. Yet questions regarding the durability of vaccine efficacy, especially against emerging variants, in this age group remain. We demonstrated previously that a two-dose regimen of stabilized prefusion Washington SARS-CoV-2 S-2P spike (S) protein encoded by mRNA encapsulated in lipid nanoparticles (mRNA-LNP) or purified S-2P mixed with 3M-052, a synthetic Toll-like receptor (TLR) 7/8 agonist, in a squalene emulsion (Protein+3M-052-SE) was safe and immunogenic in infant rhesus macaques. Here, we demonstrate that broadly neutralizing and spike-binding antibodies against variants of concern (VOCs), as well as T cell responses, persisted for 12 months. At 1 year, corresponding to human toddler age, we challenged vaccinated rhesus macaques and age-matched nonvaccinated controls intranasally and intratracheally with a high dose of heterologous SARS-CoV-2 B.1.617.2 (Delta). Seven of eight control rhesus macaques exhibited severe interstitial pneumonia and high virus replication in the upper and lower respiratory tract. In contrast, vaccinated rhesus macaques had faster viral clearance with mild to no pneumonia. Neutralizing and binding antibody responses to the B.1.617.2 variant at the day of challenge correlated with lung pathology and reduced virus replication. Overall, the Protein+3M-052-SE vaccine provided superior protection to the mRNA-LNP vaccine, emphasizing opportunities for optimization of current vaccine platforms. The observed efficacy of both vaccines 1 year after vaccination supports the implementation of an early-life SARS-CoV-2 vaccine.
Databáze: MEDLINE